Celgene Corp (CELG) 91.62 $CELG
Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...
Final Glance: Biotechnology companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Shares of CELG Up 23.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 22, 4:45PM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 23.92% as of today's recent price of $91.62.
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
Midday Glance: Biotechnology companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Bull of the Day: Epizyme (EPZM) - Bull of the Day
Kevin Cook - ZACKS - Fri Aug 22, 12:31AM CDT
Bull of the Day: Epizyme (EPZM) - Bull of the Day
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:20PM CDT
Bristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
at The Street - Thu Aug 21, 10:10AM CDT
TheStreet's Jim Cramer says investors should not worry about Gilead Sciences, especially considering its low valuation.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Celgene Corporation to Present at Investor Conferences in September
Business Wire - Thu Aug 21, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Jim Cramer's 'Mad Money' Recap: Where's the Economy Headed? Check the Railroads
at The Street - Wed Aug 20, 7:08PM CDT
Union Pacific is a better indicator than interest rates or commodity prices, Cramer says.
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
Business Wire - Wed Aug 20, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene's nab(R) technology-based chemotherapy ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a Phase I study. Multiple tumor types will be explored in the study including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). The proprietary name OPDIVO has been proposed in the U.S. and other countries, but remains subject to health authority approval.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...
Final Glance: Biotechnology companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Shares of CELG Up 23.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 22, 4:45PM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 23.92% as of today's recent price of $91.62.
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
Midday Glance: Biotechnology companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Bull of the Day: Epizyme (EPZM) - Bull of the Day
Kevin Cook - ZACKS - Fri Aug 22, 12:31AM CDT
Bull of the Day: Epizyme (EPZM) - Bull of the Day
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:20PM CDT
Bristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
at The Street - Thu Aug 21, 10:10AM CDT
TheStreet's Jim Cramer says investors should not worry about Gilead Sciences, especially considering its low valuation.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Celgene Corporation to Present at Investor Conferences in September
Business Wire - Thu Aug 21, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Jim Cramer's 'Mad Money' Recap: Where's the Economy Headed? Check the Railroads
at The Street - Wed Aug 20, 7:08PM CDT
Union Pacific is a better indicator than interest rates or commodity prices, Cramer says.
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
Business Wire - Wed Aug 20, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene's nab(R) technology-based chemotherapy ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a Phase I study. Multiple tumor types will be explored in the study including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). The proprietary name OPDIVO has been proposed in the U.S. and other countries, but remains subject to health authority approval.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
